TIDMC4XD
C4X Discovery Holdings PLC
24 July 2018
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
C4X Discovery's C4X3256 programme awarded $480k grant from the
US National Institute on Drug Abuse (NIDA)
Grant awarded to investigate efficacy of C4X3256 in preclinical
models of cocaine addiction, further demonstrating the efficacy of
C4X3256 across broad addiction indications
24 July 2018 - C4X Discovery Holdings plc (AIM:C4XD), a
pioneering drug discovery company, is pleased to announce that C4X
Discovery's C4X3256 programme has been awarded a grant from the
National Institute on Drug Abuse (NIDA, a division of National
Institute of Health (NIH)). The grant of approximately $480k will
support the pre-clinicaldevelopment of C4X3256 in cocaine use
disorder, an additional addiction indication with high unmet need.
Recently licensed to Indivior, C4X3256, an oral Orexin-1 receptor
antagonist, has demonstrated an excellent safety profile and
preclinical efficacy in models of nicotine addiction.
An estimated 1.5 million adults are suffering from cocaine use
disorder in the US alone. Current therapy relies on behavioural
approaches, while most medications used in in-patient addiction
treatment rehabilitation centers are indicated for other conditions
and are associated with poor tolerability. Orexin-1 receptor
antagonists present a new mechanism for the potential treatment of
craving and/or prevention of relapse in cocaine addiction.
Supported by the grant from NIDA, C4X Discovery will investigate
the efficacy of C4X3256 in preclinical self-administration and
reinstatement models of cocaine seeking and taking behaviours seen
as analogous to those seen in cocaine use disorder. The preclinical
studies will be co-ordinated by C4X Discovery via its drug
discovery CRO network, with the support of its development partner,
Indivior. The one-year project is expected to begin in Q3 2018.
Craig Fox, Chief Scientific Officer of C4X Discovery, commented:
"The team at C4X is delighted that the C4X3256 programme has
received this grant award from NIDA, one of the US National
Institutes of Health, in recognition of our drug discovery
expertise and the current significant unmet medical need in
substance abuse disorders. Inhibition of the Orexin-1 receptor
holds much promise as a novel clinical approach to prevent craving
and relapse in multiple addictive diseases including cocaine use
disorder. We have already demonstrated significant pre-clinical
efficacy of our novel oral candidate C4X3256 in models of nicotine
addiction and we look forward to the effectiveness in models of
cocaine addiction being investigated."
Christian Heidbreder, Chief Scientific Officer of Indivior,
commented: "We express our sincerest gratitude to NIDA for
supporting C4X3256 with our development partner C4X Discovery. A
wealth of scientific evidence supports the involvement of the
orexin system in compulsive and goal-oriented behaviours. As such,
the use of selective Orexin-1 receptor antagonists holds promise as
a new, innovative approach for the pharmacotherapeutic management
of substance use disorders."
This research is supported by the National Institute on Drug
Abuse (NIDA) of the National Institutes of Health under Award
Number R01DA043898. The content is solely the responsibility of the
authors and does not necessarily represent the official views of
the National Institutes of Health.
--ENDS--
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer +44 (0)7801 865 803
Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886
2500
Freddy Crossley, Emma Earl (Corporate Finance)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709
5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in
inflammation, neurodegeneration, immuno-oncology, addiction, and
diabetes with a number of new drug candidates identified and
further progress made towards the pre-clinical licensing
discussions. In selecting new targets C4X Discovery focuses on
high-value disease areas and maximise value from areas such as:
immuno-oncology, addiction, and diabetes. The Company recently
signed a licensing agreement with Indivior for addiction programme
worth up to $294m.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
About Indivior
Indivior is a global specialty pharmaceutical company with a
20-year legacy of leadership in patient advocacy and health policy
while providing education on evidence-based treatment models that
have revolutionized modern addiction treatment. The name is the
fusion of the words individual and endeavour, and the tagline
"Focus on you" makes the Company's commitment clear. Indivior is
dedicated to transforming addiction from a global human crisis to a
recognized and treated chronic disease. Building on its global
portfolio of opioid dependence treatments, Indivior has a strong
pipeline of product candidates designed to both expand on its
heritage in this category and address other chronic conditions and
co-occurring disorders of addiction, including alcohol use disorder
and schizophrenia. Headquartered in the United States in Richmond,
VA, Indivior employs more than 1,000 individuals globally and its
portfolio of products is available in over 40 countries worldwide.
Visit www.indivior.com to learn more.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFXLLLVDFLBBB
(END) Dow Jones Newswires
July 24, 2018 02:01 ET (06:01 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024